Evidence map›Paper›PMID 34233752›Full record

ArticleArchives of public health = Archives belges de sante publique2021

SARS-CoV-2 PCR and antibody testing for an entire rural community: methods and feasibility of high-throughput testing procedures.

Ayesha Appa, Gabriel Chamie, Aenor Sawyer, Kimberly Baltzell, Kathryn Dippell, Salu Ribeiro, Elias Duarte, Joanna Vinden, Cliahub Consortium, Jonathan Kramer-Feldman and 6 more

Open access · goldAbstract read
In one paragraph

Article in Archives of public health = Archives belges de sante publique, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Challenges Faced in Large-Scale Nucleic Acid Testing during the Sudden Outbreak of the B.1.617.2 (Delta).International journal of environmental research and public health · 2022
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Ayesha AppaUniversity of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA. Ayesha.appa@ucsf.edu.
Gabriel ChamieUniversity of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.
Aenor SawyerUniversity of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.
Kimberly BaltzellUniversity of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.
Kathryn DippellUniversity of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.
Salu RibeiroUniversity of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.
Elias DuarteUniversity of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.
Joanna VindenUniversity of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.
Cliahub ConsortiumUniversity of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.
Jonathan Kramer-FeldmanUniversity of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.
Shahryar RahdariUniversity of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.
Doug MacIntoshSan Francisco State University, San Francisco, USA.
Katherine NicholsonSan Francisco State University, San Francisco, USA.
Jonathan ImUniversity of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.
Diane HavlirUniversity of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.
Bryan GreenhouseUniversity of California, San Francisco Division of HIV, Infectious Diseases, and Global Medicine, San Francisco, CA, USA.
University of California, San Francisco · USSan Francisco State University · US

Funding

BIOLOGY OF INFECTIOUS DISEASES TRAINING PROGRAMT32AI007641 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHEW G DORSEY · 2000 to 2026
$6.9M
Mentoring translational scientists in international infectious disease researchK24AI144048 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bryan R Greenhouse · 2019 to 2026
$1.6M
Bolinas Community Land Trust Bolinas Community Land TrustChan Zuckerberg Biohub Investigator Program Chan Zuckerberg Biohub Investigator ProgramNational Institute of Allergy and Infectious Diseases 5T32AI007641-17NIAID NIH HHS K24 AI144048NIAID NIH HHS T32 AI007641
6 · The paper itself

Abstract

backgroundEarly in the pandemic, inadequate SARS-CoV-2 testing limited understanding of transmission. Chief among barriers to large-scale testing was unknown feasibility, particularly in non-urban areas. Our objective was to report methods of high-volume, comprehensive SARS-CoV-2 testing, offering one model to augment disease surveillance in a rural community.

methodsA community-university partnership created an operational site used to test most residents of Bolinas, California regardless of symptoms in 4 days (April 20th - April 23rd, 2020). Prior to testing, key preparatory elements included community mobilization, pre-registration, volunteer recruitment, and data management. On day of testing, participants were directed to a testing lane after site entry. An administrator viewed the lane-specific queue and pre-prepared test kits, linked to participants' records. Medical personnel performed sample collection, which included finger prick with blood collection to run laboratory-based antibody testing and respiratory specimen collection for polymerase chain reaction (PCR).

resultsUsing this 4-lane model, 1,840 participants were tested in 4 days. A median of 57 participants (IQR 47-67) were tested hourly. The fewest participants were tested on day 1 (n = 338 participants), an intentionally lower volume day, increasing to n = 571 participants on day 4. The number of testing teams was also increased to two per lane to allow simultaneous testing of multiple participants on days 2-4. Consistent staffing on all days helped optimize proficiency, and strong community partnership was essential from planning through execution.

conclusionsHigh-volume ascertainment of SARS-CoV-2 prevalence by PCR and antibody testing was feasible when conducted in a community-led, drive-through model in a non-urban area.

Indexed as

COVID-19COVID-19 diagnostic testingFeasability StudiesRural Population

Identifiers

PMID34233752
PMCPMC8261397
OpenAlexW3180218631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.